Magnetic Resonance ImagingHepatocellular CarcinomaScreeningContrast-enhanced US
Investigational drug(s) / intervention(s)
MRI
MRI: To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
Study summary
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI.
Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.
* Informed Consent signed by the subject
Exclusion Criteria:
* History of HCC
* History of other malignancy
* Prior liver nodule categorized as LI-RAD 4, 5 or M
* History of liver transplantation
* Pregnancy
* MRI or MRI contrast agent precaution
* Any other condition making the patient unsuitable for the study
* Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study
Primary outcome measure(s)
To compare the diagnostic performance of US+/- CEUS and AMRI for HCC detection in an at-risk population — Through study completion, an average of 1 year. The patients will undergo all the normal follow-up according to clinical recommendations, consisting of a bi-annual clinical visit in the gastro-enterology department and an US. The US will be followed by CEUS in case of suspicious lesion. On the same week, the study participants will undertake MRI.
The data of the full MRI will be used to reconstruct two different AMRI sets for reading: non-contrast (NC-) and dynamic (Dyn-) AMRI.
The endpoint is the rate of HCC detection. Outcome measures will be compared in terms of ROC curve and AUC.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
